News Archive

The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.

2017

October

Media Release / Oct 30, 2017

Novartis releases results of first controlled, randomized clinical trial specifically designed for pediatric multiple sclerosis (MS)

Read More

September

Media Release / Sep 26, 2017

Ride for Life: Novartis employees embark on a 600-km bike ride for breast cancer

Read More
Media Release / Sep 13, 2017

Cosentyx® demonstrates sustained results in psoriasis with 5-year Phase III data

Read More

June

Media Release / Jun 22, 2017

Psoriasis bodypainting campaign puts dermatologists ‘in their patients’ shoes’

Read More
Media Release / Jun 22, 2017

Top 10 Novartis Facts and Figures

Read More
Media Release / Jun 20, 2017

PrXolair® added to seven Canadian public drug plans to treat chronic idiopathic urticaria (hives)

Read More
Media Release / Jun 19, 2017

Combination treatment PrTafinlar® (dabrafenib) plus PrMekinist® (trametinib) approved by Health Canada to treat BRAF V600-positive metastatic non-small cell lung cancer (NSCLC) after prior systemic therapy1

Read More
Media Release / Jun 15, 2017

Combination treatment (Pr)Tafinlar® (dabrafenib) plus (Pr)Mekinist® (trametinib) approved by Health Canada to treat BRAF V600- positive metastatic non-small cell lung cancer (NSCLC) after prior systemic therapy

Read More

May

Media Release / May 11, 2017

21 years of community service: Novartis takes part in annual Community Partnership Day in Canada

Read More
Media Release / May 09, 2017

Novartis heart failure treatment PrEntresto™ (sacubitril/valsartan) now available to patients in Ontario through the public provincial drug plan

Read More

Pages